In Vitro Susceptibility to Miltefosine of <i>Leishmania infantum</i> (syn. <i>L.</i> <i>chagasi</i>) Isolates from Different Geographical Areas in Brazil

In Vitro Susceptibility to Miltefosine of <i>Leishmania infantum</i> (syn. <i>L.</i> <i>chagasi</i>) Isolates from Different Geographical Areas in Brazil

Treatment of visceral leishmaniasis in Brazil still relies on meglumine antimoniate, with less than ideal efficacy and safety, making new therapeutic tools an urgent need. The oral drug miltefosine was assayed in a phase II clinical trial in Brazil with cure rates lower than previously demonstrated...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Caroline Ricce Espada, Erica V. de Castro Levatti, Mariana Côrtes Boité, Dorcas Lamounier, Jorge Alvar, Elisa Cupolillo, Carlos Henrique Nery Costa, Joelle Rode, Silvia R. B. Uliana
Formatua: Artikulua
Hizkuntza:English
Argitaratua: MDPI AG 2021-06-01
Saila:Microorganisms
Gaiak:
clinical strains
miltefosine
susceptibility
visceral leishmaniasis
Sarrera elektronikoa:https://www.mdpi.com/2076-2607/9/6/1228

Internet

https://www.mdpi.com/2076-2607/9/6/1228

Antzeko izenburuak